What is the purpose of the AIM2CERV study?
The goal of the AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence) study is to develop a treatment to prevent or reduce the risk of cervical cancer recurrence after primary, standard of care treatment in women who are at high risk of recurrence.
AIM2CERV is a global, randomized, 450-patient study evaluating axalimogene filolisbac (ADXS11-001) as an adjuvant therapy that follows primary treatment with chemotherapy and radiation in women living with high-risk locally advanced carcinoma of the cervix (HRLACC).
Research has shown that HRLACC comes back in approximately 50 percent of women who are treated with chemoradiation therapy. This trial may show whether axalimogene filolisbac can prevent that recurrence.
The trial compares disease-free survival (DFS) in women receiving axalimogene filolisbac (ADXS11-001) to DFS in patients receiving placebo.
An adjuvant therapy is a therapy that is given shortly after initial treatment for cancer to prevent the cancer from recurring.